Evidence map›Paper›PMID 37895434›Full record

ArticleLife (Basel, Switzerland)2023

Safety and Efficacy of an Innovative Everolimus-Coated Balloon in a Swine Coronary Artery Model.

Christos S Katsouras, Alexandros Tousis, Georgios Vasilagkos, Arsen Semertzioglou, Athanassios Vratimos, Ioanna Samara, Georgia Karanasiou, Vasileios S Loukas, Grigorios Tsigkas, Dimitrios Fotiadis and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Life (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Christos S Katsouras2nd Department of Cardiology, University Hospital of Ioannina, University of Ioannina, 45110 Ioannina, Greece.
Alexandros TousisDepartment of Cardiology, University Hospital of Patras, 26504 Patras, Greece.
Georgios VasilagkosDepartment of Cardiology, University Hospital of Patras, 26504 Patras, Greece.ORCID 0000-0001-8256-2928
Arsen SemertzioglouRontis Hellas SA, 41500 Larissa, Greece.
Athanassios VratimosRontis Hellas SA, 41500 Larissa, Greece.
Ioanna Samara2nd Department of Cardiology, University Hospital of Ioannina, University of Ioannina, 45110 Ioannina, Greece.
Georgia KaranasiouDepartment of Biomedical Research, Institute of Molecular Biology and Biotechnology, Department of Materials Science and Engineering, Unit of Medical Technology and Intelligent Information Systems, University of Ioannina, 45110 Ioannina, Greece.ORCID 0000-0001-9478-0375
Vasileios S LoukasDepartment of Biomedical Research, Institute of Molecular Biology and Biotechnology, Department of Materials Science and Engineering, Unit of Medical Technology and Intelligent Information Systems, University of Ioannina, 45110 Ioannina, Greece.
Grigorios TsigkasDepartment of Cardiology, University Hospital of Patras, 26504 Patras, Greece.ORCID 0000-0002-2779-0765
Dimitrios FotiadisDepartment of Biomedical Research, Institute of Molecular Biology and Biotechnology, Department of Materials Science and Engineering, Unit of Medical Technology and Intelligent Information Systems, University of Ioannina, 45110 Ioannina, Greece.ORCID 0000-0002-7362-5082
Lampros K Michalis2nd Department of Cardiology, University Hospital of Ioannina, University of Ioannina, 45110 Ioannina, Greece.
Periklis DavlourosDepartment of Cardiology, University Hospital of Patras, 26504 Patras, Greece.
Anargyros N MoulasGeneral Department, University of Thessaly, 41500 Larissa, Greece.ORCID 0000-0002-4681-6174
University of Ioannina · GRGeneral University Hospital of Patras · GRUniversity of Thessaly · GR

Funding

the European Regional Development Fund of the European Union and Greek national funds through the Operational Program Competitiveness, Entrepreneurship and Innovation, under the call Research - Create - Innovate T2EDK-03677
6 · The paper itself

Abstract

backgroundDrug-coated balloons have been used as a non-stenting treatment in coronary and peripheral artery disease. Until recently, only sirolimus- and paclitaxel-coated balloons have been investigated in clinical trials. We evaluated the safety and efficacy of an innovative everolimus-coated balloon (ECB) in a swine coronary artery model.

methodsthirty-two swine coronary arteries were prepared through dilatation with a non-coated angioplasty balloon in a closed-chest model. During a period of 90 days, the following four groups (four animals per group, two coronary arteries per animal) were compared for safety and efficacy: A, Rontis ECB with 2.5 μg/mm

resultsDifferences in local biological effects (arterial reaction scores) and surface of intimal area (mm

conclusionsECB was safe and effective in a porcine coronary artery model. The dose of everolimus may play a role in the biocompatibility of the balloon.

Indexed as

angioplastycoronary arteriesdrug coated ballooneverolimusporcine model

Identifiers

PMID37895434
PMCPMC10607937
OpenAlexW4387638890

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.